Commentary: can circulating HER-2 extracellular domain predict response to trastuzumab in HER-2-negative breast cancer?
- PMID: 18448550
- DOI: 10.1634/theoncologist.2008-0050
Commentary: can circulating HER-2 extracellular domain predict response to trastuzumab in HER-2-negative breast cancer?
Comment on
-
Trastuzumab plus paclitaxel or docetaxel in HER-2-negative/HER-2 ECD-positive anthracycline- and taxane-refractory advanced breast cancer.Oncologist. 2008 Apr;13(4):361-9. doi: 10.1634/theoncologist.2007-0207. Oncologist. 2008. PMID: 18448549 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous